薏苡仁油对高糖环境下人视网膜血管内皮细胞增殖和VEGF表达的影响

目的:研究不同浓度的薏苡仁油对体外高糖条件下培养的人视网膜血管内皮细胞(HRCECs)增殖及血管内皮生长因子(VEGF)表达的影响。方法:将新鲜人眼球提取的HRCECs进行体外培养,最终用于实验的为生长良好的第3~4代细胞,实验分为空白对照组、低糖对照组、高糖对照组,高糖+不同浓度(50μL/mL,100μL/mL,200μL/mL)薏苡仁油组。不同浓度的薏苡仁油对体外培养的HRCECs增殖的抑制作用是通过用噻唑蓝比色法(MTT)检测。各分组HRCECs中VEGF的表达由免疫细胞化学法检测。结果:MTT比色法结果显示:不同浓度的薏苡仁油作用于体外培养的HRCECs 48h,其细胞增殖抑制与高糖对照组相比有显著性差异(P<0.05)。48h内呈浓度依赖性。而低糖对照组与高糖对照组差异无统计学差异(P>0.05)。免疫细胞化学检测法表明:用50,100,200μL/mL的薏苡仁油作用于高糖下HRCECs 48h,高糖+不同浓度薏苡仁油组与高糖对照组相比VEGF表达下降明显(P<0.05),将高糖+不同浓度薏苡仁油组之间进行两两比较亦具有统计学意义(P<0.05)。且呈浓度依赖性。高糖对照组与低糖对照组相比,VEGF表达明显(P<0.05)。结论:薏苡仁油可抑制高糖环境下HRCECs的增殖和VEGF的表达。     

莪术油对高糖下视网膜血管内皮细胞增殖及VEGF表达的影响

目的：研究不同浓度的莪术油对高糖条件下体外培养的人视网膜血管内皮细胞(human retinal capillary endothelial cells, HRCECs)增殖、调亡及血管内皮细胞生长因子(vascular endothelial growth factor, VEGF)表达的影响。

方法：体外培养从角膜移植术后新鲜人眼球提取的HRCECs。取生长良好的第 3～4代细胞用于实验,实验分为低糖对照组、高糖对照组、高糖+(60,80,100,120μg/mL)不同浓度莪术油组,用噻唑蓝(MTT)比色法检测HRCECs的增殖,通过免疫细胞化学法观察各分组HRCECs中VEGF的表达情况。

结果：MTT比色法结果显示：高糖对照组与低糖对照组没有显著差异(P>0.05),用60,80,100,120μg/mL的莪术油处理高糖下HRCECs作用24h高糖+不同浓度莪术油组与高糖对照组相比具有显著性差异(P<0.05),高糖+不同浓度莪术油组之间呈时间和浓度的显著性差异(P<0.05)。免疫细胞化学检测显示：与低糖对照组相比,高糖对照组VEGF表达明显(P<0.05),用80,100,120μg/mL的莪术油处理高糖下HRCECs 24h,高糖+不同浓度莪术油组与高糖对照组相比VEGF表达有显著性差异(P<0.05),高糖+不同浓度莪术油组之间两两比较均具有显著性差异(P<0.05)。

结论：莪术油可抑制高糖下人视网膜血管内皮细胞增殖和VEGF表达。     

人参皂苷Rg3对高糖下视网膜血管内皮细胞增殖及ICAM-1表达的影响

目的:研究人参皂苷Rg3对体外培养的高糖条件下人视网膜血管内皮细胞(human retinal capillary endothelial cell,HRCEC)增殖与细胞间黏附分子-1(intercellular adhesionmolecule-1,ICAM-1)表达的影响。方法:体外培养从角膜移植术后新鲜人眼球提取的HRCECs。取生长良好的第3~4代细胞用于实验,实验分为低糖对照组、高糖对照组、高糖+不同浓度Rg3组,用噻唑蓝(MTT)比色法检测HRCEC的增殖。通过免疫细胞化学法观察各分组HRCEC ICAM-1的表达情况。结果:MTT比色法结果显示,高糖对照组与低糖对照组没有显著差异(P>0.05),用10,20,40,80,160mg/L的人参皂苷Rg3处理高糖下HRCEC24,48,72h与高糖对照组相比具有显著性差异(P<0.05),高糖+不同浓度Rg3组之间呈时间和浓度的显著性差异(P<0.05)。免疫细胞化学检测显示,与低糖对照组相比,高糖对照组ICAM-1表达明显(P<0.05),用40,80,160mg/L的人参皂苷Rg3处理高糖下HRCEC48h与高糖对照组相比ICAM-1表达有显著性差异(P<0.05),高糖+不同浓度Rg3组之间两两比较均具有显著性差异(P<0.05)。结论:人参皂苷Rg3可抑制高糖下视网膜血管内皮细胞增殖和ICAM-1表达。     

姜黄素对高糖诱导的人视网膜血管内皮细胞增殖及VEGF和NF-κB p65表达的抑制作用

目的：观察不同浓度姜黄素对体外高糖诱导的人视网膜血管内皮细胞(HRCECs)增殖及血管内皮生长因子(VEGF)、核因子-κB(NF-κB)p65表达的影响。

方法：用高糖培养基模拟糖尿病环境建立HRCECs体外高糖模型,将培养的细胞分为：正常对照组、高糖对照组、高糖+20、40、80μmol/L姜黄素组,分别用CCK-8法检测姜黄素干预后HRCECs的增殖能力,用Western-blot及免疫细胞化学法检测VEGF、NF-κB p65的表达。

结果：CCK-8法结果示：与正常对照组比较,高糖显著促进HRCECs增殖(P<0.01),各浓度姜黄素作用12、24、48h后与高糖对照组比较,细胞增殖均有明显抑制作用(P<0.01),且呈浓度与时间依赖性。Western-blot结果示：与正常对照组比较,高糖对照组中VEGF-A、NF-κB p65表达显著增加(P<0.01),各浓度姜黄素作用12、24、48h后与高糖对照组比较,VEGF-A、NF-κB p65的表达显著减少,且随着浓度增加、时间延长抑制作用增强,各加药组间两两比较均有差异(P<0.01)。免疫细胞化学法结果示：与正常对照组相比,高糖对照组VEGF表达显著增加(P<0.01),各浓度姜黄素干预24h后与高糖对照组比较,VEGF表达逐渐下降(P<0.01),各加药组间两两比较均有差异(P<0.01)。

结论：姜黄素可呈浓度与时间依赖性地抑制高糖诱导的HRCECs增殖以及VEGF、NF-κB p65的表达,这种增殖抑制作用可能与其下调VEGF、NF-κB p65表达有关。     

丙丁酚对高糖环境下人视网膜血管内皮细胞增殖及VEGF表达的影响

目的研究不同浓度的丙丁酚(普罗布考,Probucol)对体外培养的高糖环境下人视网膜微血管内皮细胞(human retinal capillary endothelial cells,HRCEC)增殖及血管内皮细胞生长因子(vascular endothelial growth factor,VEGF)表达的影响。方法 体外培养从角膜移植术后新鲜人眼球提取的HRCEC。取生长良好的第3-4代细胞用于实验,实验分为低糖对照组、高糖对照组、高糖+不同浓度丙丁酚(5μmol.L-1、10μmol.L-1、20μmol.L-1、40μmol.L-1、80μmol.L-1)组,用噻唑蓝比色法(MTT)检测24h不同浓度的丙丁酚对其增殖的抑制作用。免疫细胞化学法检测低糖对照组、高糖对照组和不同浓度丙丁酚(5μmol.L-1、40μmol.L-1、80μmol.L-1)组HRCEC中VEGF的表达。结果 MTT比色法结果显示:不同浓度的丙丁酚作用于原代培养HRCEC24h,细胞增生抑制率分别为8.40%、20.84%、34.90%、45.32%、55.38%。一定质量浓度范围内丙丁酚可抑制高糖环境下HRCEC的增殖(P<0.05),24h内呈质量浓度依赖性。低糖对照组与高糖对照组相比差异无统计学意义(P=0.067>0.05)。低糖对照组、高糖对照组与丙丁酚浓度分别为5μmol.L-1、40μmol.L-1、80μmol.L-1作用于HRCEC24h,免疫细胞化学背景灰度值与阳性灰度值之差分别为28.75±3.77、71.93±8.37、54.67±4.33、41.43±3.45、29.18±3.37。与高糖对照组相比,加药组作用24h VEGF表达明显下降,差异均有统计学意义(均为P<0.05),且呈质量浓度依赖性。与低糖对照组相比,高糖对照组VEGF的表达明显增加(P<0.05)。结论 丙丁酚对体外培养的高糖环境下HRCEC的增殖及高糖引起VEGF表达的上调具有抑制作用。     

银杏叶提取物对高糖环境下人视网膜血管内皮细胞增殖、凋亡的影响

目的:研究不同浓度的银杏叶提取物(ginkgo biloba ex-tract,GBE)对体外培养的高糖环境下人视网膜微血管内皮细胞(human retinal capillary endothelial cells,HRCECs)增殖和凋亡的影响。方法:体外培养从角膜移植术后新鲜人眼球提取的HRCECs。取生长良好的第3～4代细胞用于实验,实验分为低糖对照组、高糖对照组、高糖+不同浓度GBE组,用噻唑蓝(MTT)比色法检测HRCECs的增殖。吖啶橙(AO)/溴乙锭(EB)荧光双染色、流式细胞术检测HRCECs的凋亡率,并在荧光显微镜下观察荧光染色后HRCECs凋亡形态学改变。结果:MTT比色法结果显示:用12.5,25.0,50.0,100.0mg/L的GBE处理高糖环境下HRCECs,作用24,48,72h,高糖+不同浓度GBE组与高糖对照组相比具有显著性差异(P<0.05),高糖+不同浓度GBE组之间两两比较均具有显著性差异(P<0.05)。AO/EB荧光染色法、流式细胞术检测细胞凋亡率显示:高糖+不同浓度GBE组与高糖对照组比较均有显著性差异(P<0.05),高糖对照组显著高于低糖对照组(P<0.05)。荧光显微镜下观察到活细胞,早期凋亡细胞,晚期凋亡细胞,非凋亡的死亡细胞生物学形态改变的特征。结论:GBE促进高糖环境下HRCECs的增殖,抑制其凋亡。     

阿魏酸钠对高糖环境下人视网膜内皮细胞表达的影响

目的:研究体外环境下高糖培养的人视网膜血管内皮细胞(human retinal capillary endothelial cells,HRCEC)经过不同浓度的阿魏酸钠(sodium ferulate,SF)作用后的增殖以及血管内皮细胞生长因子(vascular endothelial growth factor,VEGF)表达的影响。方法:对眼科手术新鲜的人角膜移植术后眼球进行取材并进行HRCEC的原代培养。进行实验的为生长良好的第3～4代细胞,实验分为空白对照组、低糖对照组、高糖对照组、高糖+不同浓度阿魏酸(1mg/L,2mg/L,3mg/L,4mg/L)组,用噻唑蓝比色法(MTT)检测48h后不同浓度的阿魏酸钠对其增殖的抑制作用。免疫细胞化学法用于检测低糖对照组、高糖对照组和不同浓度阿魏酸(1mg/L,2mg/L,4mg/L)组HRCEC中VEGF的表达。结果:MTT比色法结果表明:48h后不同浓度的阿魏酸钠分别作用于原代培养的HRCEC细胞增生抑制率分别为46.97%,61.55%,76.91%和83.47%。一定质量浓度范围内阿魏酸钠对高糖环境下HRCEC具有明显的增殖抑制作用(P<0.05)。低糖对照组与高糖对照组吸光度A结果相比,差异无统计学意义(P=0.068>0.05)。低糖对照组、高糖对照组与浓度分别为1mg/L,2mg/L,4mg/L的阿魏酸钠作用组作用于HRCEC 48h后免疫细胞化学背景灰度值与阳性灰度值之差分别为28.27±1.62,93.67±0.81,72.67±2.89,53.73±1.70,30.93±3.72。通过48h后加药组和高糖对照组相比,VEGF表达下降明显,且均有统计学意义(均为P<0.05),具有质量浓度依赖性。与低糖对照组相比,高糖对照组VEGF的表达明显增加(P<0.05)。结论:阿魏酸钠对体外培养的高糖环境下HRCEC的增殖及高糖引起VEGF表达具有抑制作用。     

P97抵抗高糖培养的人视网膜血管内皮细胞增殖

目的:研究含缬酪肽蛋白(valosin-containing protein,P97)对高糖培养的人视网膜血管内皮细胞的作用。方法:体外高糖培养人视网膜血管内皮细胞(HRCECs),转染P97的RNA干扰质粒到HRCECs,抑制P97的表达,观察血管内皮生长因子(VEGF)的mRNA水平变化,同时观察HRCECs增殖的变化。结果:RNA干扰P97组和对照组的VEGF/actin分别为:0.21±0.03和0.10±0.01,两组差异有显著性(P<0.05),RNA干扰P97组和对照组,HRCECs在G1期细胞分别为44.05%±3.62%、25.21%±3.20%,两组比较差异有显著性(P<0.05)。结论:当P97表达受抑制后,VEGF的表达增高,HRCECs的增殖增强,这些变化可能与DR的发生发展相关。     

雷公藤红素对高糖环境下大鼠视网膜血管内皮细胞VEGF和PEDF表达的影响

目的观察雷公藤红素对高糖环境下大鼠视网膜血管内皮细胞VEGF和PEDF表达的影响。方法将体外培养的大鼠视网膜血管内皮细胞分为空白对照组、高糖组、高糖+雷公藤红素(0.05mg·L-1)组,进行相应处理后分别用免疫细胞化学及ELISA法检测细胞中VEGF和PEDF的表达。结果免疫细胞化学灰度值测定,空白组、高糖组及高糖+雷公藤红素组VEGF表达分别为74.40±4.19、110.12±7.32、78.11±5.81,PEDF表达量分别为124.65±6.01、88.73±7.84、93.31±5.67;ELISA结果显示空白组、高糖组及高糖+雷公藤红素组VEGF表达量分别为(155.21±13.36)ng·L-1、(237.69±19.41)ng·L-1、(168.57±26.32)ng·L-1,PEDF表达量分别为(251.37±17.95)ng·L-1、(178.35±25.36)ng·L-1、(191.58±31.37)ng·L-1,与正常对照组相比,高糖组VEGF表达增高(P<0.05),PEDF表达减少(P<0.05);与高糖组相比,高糖+雷公藤红素组VEGF表达减少(P<0.05),PEDF表达无明显差异性(P>0.05)。结论雷公藤红素能减少高糖环境下大鼠视网膜血管内皮细胞中VEGF表达,对PEDF表达的影响不明显。     

人脐带间充质干细胞源外泌体对高糖环境下RPE细胞自噬和VEGF表达的影响

目的:探讨人脐带间充质干细胞(hUMSC)源外泌体对高糖环境下ARPE-19细胞自噬及VEGF表达情况的影响。方法:原代培养hUMSC,分离纯化hUMSC外泌体,Western blot鉴定hUMSC外泌体标志蛋白CD63表达,透射电镜观察外泌体形态。将体外培养的ARPE-19细胞随机分为对照组、高糖组和外泌体+高糖组(75μg/mL外泌体预处理)。培养48h后,电镜观察三组细胞内自噬体的超微结构,MTT法检测各组细胞增殖情况,Western blot检测各组细胞中自噬标志性蛋白LC3B、Beclin-1及p62的表达,ELISA法检测细胞上清液中VEGF的质量浓度。结果:分离纯化后的外泌体为直径30~100nm的球状膜性囊泡,表达特异性标识蛋白CD63。外泌体+高糖组中自噬体的数量明显少于高糖组。外泌体+高糖组的细胞增殖率较高糖组明显升高(P<0.01)。对照组、高糖组、外泌体+高糖组细胞中LC3B-Ⅱ/Ⅰ、Beclin-1和p62值分别为(0.214±0.019、0.461±0.067和0.332±0.079),(0.186±0.029、0.615±0.044和0.464±0.046)和(0.771±0.051、0.364±0.016和0.547±0.039)。高糖组细胞中LC3B-Ⅱ/Ⅰ值和Beclin-1值均明显高于对照组和外泌体+高糖组(均P<0.05),高糖组细胞中p62值明显低于对照组和外泌体+高糖组(均P<0.01),外泌体+高糖组VEGF的质量浓度较高糖组明显降低(P<0.01)。结论:高糖环境激活ARPE-19细胞自噬,并促进其VEGF的表达。hUMSC外泌体可有效抑制高糖环境下ARPE-19细胞自噬水平,并下调VEGF的表达。     

A review of techniques and outcomes of endothelial keratoplasty in congenital hereditary endothelial dystrophy

Congenital hereditary endothelial dystrophy affects the Descemet membrane and endothelium, resulting in corneal decompensation. Penetrating keratoplasty (PKP) has been the gold-standard surgical management until recently; however, at present, endothelial keratoplasty (DSEK/DSAEK/n-DSEK: Descemet-stripping or non-Descemet stripping endothelial keratoplasty and DMEK/n-DMEK: Descemet membrane endothelial keratoplasty) is being preferred due to lesser intraoperative and postoperative complications, early visual recovery, and comparable visual outcomes. Endothelial keratoplasty (EK) can be challenging, especially in pediatric eyes with CHED due to smaller eyeballs, shallow anterior chambers, phakic status, and poor intraoperative visibility due to thick and hazy corneas. A total of 198 articles matched our search strategy. After screening for duplication and going through the titles and abstracts, 12 relevant original articles, one case series, and six case reports were included in this review. Various surgical modifications have to be adopted in comparison to adult eyes to overcome the aforementioned difficulties. Regardless, studies have shown favorable visual outcomes with better graft survival and fewer complications in eyes that underwent EK compared to PKP. Hence, timely surgical intervention and strict amblyopia management can result in better final visual outcomes. The purpose of this review is to summarize various intraoperative difficulties and the surgical modifications required, different surgical techniques, visual and graft-related outcomes, and various complications of EK in CHED eyes.     

Clinical results of non-Descemet stripping endothelial keratoplasty

AIM: To investigate the impact of non-Descemet stripping endothelial keratoplasty (non-DSEK) on graft rejection rate, and its overall procedural effectiveness in patients. METHODS: Non-DSEK was performed on 65 eyes of 64 patients, and the procedural outcomes, including rejection episodes, failure and dislocation of the grafts, best corrected visual acuity (BCVA), endothelial cell density (ECD), and other complications, were analyzed retrospectively. RESULTS: Of the 65 eyes, 63 recovered from bullous keratopathy with a clear cornea. The mean follow-up time was 26.4mo (range, 6-84mo). The mean BCVA improved from 1.70 logMAR preoperatively to 0.54 logMAR at 3mo, 0.46 logMAR at 6mo, and 0.37 logMAR at 1y after surgery. The postoperative donor ECD of the 25 patients who successfully underwent specular microscopic examination was 1918±534 cells/mm2 (range, 637 to 3056 cells/mm2), and the mean endothelial cell loss was 41.9% at 24mo postoperatively. One eye developed secondary glaucoma and required regrafting via penetrating keratoplasty (PKP). Another eye had postoperative graft failure due to rejection at 26mo. Postoperative graft dislocation occurred in eight eyes. All of the eight dislocated grafts were reattached using air reinjection. CONCLUSION: Immunological graft rejection of the donor graft rarely occurs in non-DSEK. Therefore, non-DSEK is a safe, concise, and effective alternative to restore corneal decompensation when the Descemet membrane is disease-free.     

One-Year Observation of Transplanted Human Corneal Endothelium

In 34 penetrating corneal transplants, endothelial photographs were taken preoperatively and at four postoperative intervals: four days, three weeks, three months, and one year. Preoperative corneas from older donors had larger and more variably sized endothelial cells. Although the mean endothelial cell loss at the four day examination was only 17%, it continued at a linear rate so that by one year almost half of the central endothelial cells were gone. The continued cell loss was not significantly affected by the operative cell loss, the presence of a lens postoperatively, or the recipient endothelial status. Six of the 34 transplants sustained documented episodes of allograft rejection, but their endothelial cell losses were minimized by prompt treatment with corticosteroids. The cell losses in the 20 phakic and 14 aphakic transplants were similar at both the four-day and one-year intervals, although the aphakic grafts were thicker at both times. Two additional transplants with vitreous touch to the graft endothelium sustained large continuing endothelial cell losses despite maintenance of clear, thin transplants.     

人脐血内皮祖细胞体外培养和鉴定的研究(英文)

目的:阐述从人脐血单核细胞分离培养EPCs的方法,并观察EPCs体外增殖分化过程中内皮细胞特异性抗原的表达,为进一步研究EPCs在缺血性视网膜疾病的临床应用奠定基础。方法:采用密度梯度离心方法获得脐带血单个核细胞,体外进行诱导、分化和扩增,通过免疫组化和流式细胞仪分析等技术对脐血来源的EPCs进行鉴定,在我们的研究中主要分析CD34,血管内皮细胞生长因子受体-2(VEGFR-2),EPCs特异性抗原CD133,以及内皮细胞特异性抗原CD31和第八因子相关抗原(vWF)的表达情况。同时我们通过分析细胞摄取乙酰化低密度脂蛋白(acLDL)和结合植物凝集素的能力进一步鉴定细胞。结果:脐带血单个核细胞在培养早期主要为梭形细胞,逐渐呈现铺路石样外观;在细胞培养至第7d,贴壁细胞流式细胞仪分析显示,CD133, CD34和VEGFR-2的阳性率分别为17.8%±3.7%, 22.1%±4.4%和81.5%±5.0% ;免疫组化染色结果显示CD31、vWF的表达率分别为92.7%±2.2%和73.3%±4.2%;免疫荧光染色结果表明83.0%±4.3%的贴壁细胞DiI-acLDL和FITC-UEA-I染色均阳性。结论:本实验证明在体外特定的培养条件可以从脐带血单个核细胞中分离培养出EPCs,为进一步研究EPCs与视网膜新生血管的关系以及EPCs治疗缺血性眼底的临床研究奠定了基础。     

Comparison of penetrating and endothelial keratoplasty in patients with iridocorneal endothelial syndrome: A registry study

Background

To compare graft survival of endothelial keratoplasty (EK) versus penetrating keratoplasty (PK) in patients with iridocorneal endothelial (ICE) syndrome and identify ocular features associated with graft survival.

Methods

Observational, prospective, cohort study. A total of 30 806 first grafts performed between 1985 and 2020 were identified through the Australian Corneal Graft Registry and included in this observational, prospective cohort study. A total of 196 eyes underwent a primary corneal graft for ICE syndrome. Kaplan–Meier graft survival plots and Chi-squared tests were performed to identify graft survival rates for EK and PK. A history of raised intraocular pressure (IOP) was also recorded and analysed. Graft survival of eyes with ICE syndrome were compared to that of other indications.

Results

Grafts performed for ICE syndrome increased to 0.8% of all cases during the 2005 to 2020 period compared with 0.5% between 1985 to 2004 (χ²=9.35, p = 0.002). From 2010, EK surpassed PK as the preferred graft type. Survival of primary grafts in eyes with ICE syndrome was lower than for other indications (log-rank = 56.62, p < 0.001). Graft survival was higher following PK than Descemet stripping (automated) endothelial keratoplasty (DS(A)EK) (log-rank = 10.56, p = 0.001). Graft survival was higher in eyes without a history of raised IOP compared to those with a reported history of raised IOP (log-rank = 13.06, p < 0.001).

Conclusions

ICE syndrome carries a poor prognosis for graft survival. DS(A)EK had a poorer prognosis than PK. A history of raised IOP is associated with higher risk of graft failure.     

Culture and identification of endothelial progenitor cells from human umbilical cord blood

AIM: To elucidate a simple method for isolating endothelial progenitor cells (EPCs) from human umbilical cord blood mononuclear cells and observe the endothelial cell-specific expression profile during proliferation and differentiation in vitro. · METHODS: Human umbilical cord blood were isolated by Percoll density gradient centrifugation from human cord blood and cultured in vitro. The adherent cells were then identified by immunohistochemical staining and flow cytometric analysis. CD34, vascular endothelial growth factor receptor-2 (VEGFR-2), EPCs specific antigen CD133, as well as endothelial cell specific markers CD31 and vWF were used. The cells were characterized by acetylated LDL(acLDL) up-taking and lectin binding by direct fluorescentstaining. · RESULTS: During culture, the attached cells exhibited spindle-shape in early stage, and gradually display endothelium- like cobblestone morphology with outgrowth. On day 7, flow cytometric analysis showed that the positive staining rate of attached cells for CD133, CD34 and VEGFR-2 were 17.8%±3.7%, 22.1%±4.4% and 81.5%±5.0%, respectively. While, immunohistochemical staining showed that the adherent cells were positive to CD31 and vWF at the rate of 92.7%±2.2% and 73.3%±4.2%, respectively. By direct fluorescentstaining, we observed that 83.0%±4.3% of the attached cells were double positive for DiI-acLDL and FITC-UEA-I. · CONCLUSION: EPCs can be separated from human cord blood under certain conditions in vitro. This observation may provide a basis for study of relationship between EPCs and retinal neovascularization, as well as further clinical application of EPCs in ischemic retinal lesions.     

后弹力层角膜内皮移植术应用与手术技术

角膜内皮移植(endothelial keratoplasty,EK)是针对内皮细胞功能障碍的靶向性治疗方法.目前已成为国际上治疗角膜内皮病变的首选方法.而后弹力层角膜内皮移植术(Descemet's membrane endothelial keratoplasty,DMEK)是目前EK最新技术,也称为小切口角膜内皮移植术,从解剖学角度完美恢复了角膜组织的正常结构,可更好更快恢复视力,且术后排斥反应显著降低,受到了广泛关注和认可.然而,DMEK作为一项新技术,虽然具有显著的优点,也面临着技术上的挑战.最受关注的是供体制备过程中内皮片的丢失、植入受体的展开和位置调整.目前随着手术方法和设备的不断改进,植入技术不断改进,学习曲线正在逐渐减低,越来越多的眼科医生掌握了该技术.由于角膜材料与手术适应证等限制,目前我国尚无开展DMEK的报道.     

角膜后弹力膜内皮移植术研究进展

角膜后弹力膜内皮移植术由于具有相对较低的移植排斥率以及较好的视力预后等优势,目前已成为部分发达国家治疗角膜内皮失代偿的主流手术方式,但限于手术难度较高,学习曲线较长,中国人前房偏浅,加之国内角膜内皮病变往往合并有其他较复杂的眼部疾病,目前国内尚未普遍开展这一手术。本文就角膜后弹力膜内皮移植术的手术适应证、供体植片制备(...     

利用后弹力层撕除术建立兔眼角膜内皮失代偿模型的评估

目的利用后弹力层撕除术建立一种新的角膜内皮失代偿模型以便更好地了解该手术的组织反应。方法根据手术方法的不同将40只新西兰成年兔平均分为4组：角膜内皮刮除组、后弹力层撕除组、后弹力层撕除角膜内皮移植术（DSEK）组及DSEK供体组;右眼为手术眼。每组定期通过角膜内皮活体染色,眼前节照相和UBM至少观察2个月。结果后弹力层撕除组角膜始终保持混浊,角膜内皮刮除组和DSEK组角膜逐渐透明,角膜厚度逐渐降低。活体染色显示角膜后弹力层撕除组术后2个月仍无角膜内皮生长。结论后弹力层撕除术建立的角膜内皮失代偿模型显示了后弹力层撕除后角膜内皮愈合过程,可用于角膜内皮移植的研究。     

角膜内皮移植技术的发展

角膜内皮移植术已成为治疗各种原因引起的角膜内皮功能失代偿的首选术式.角膜内皮移植手术与穿透性角膜移植手术相比,其较好地保持了眼前节的生物学完整性,术后视力恢复更快、更好,大大降低术后并发症等.本文就角膜内皮移植技术的发展过程,主要手术方式,手术的优缺点及术后并发症等进行综述,以期为临床应用提供参考.